• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Government Plans Three Large Phase 3 COVID-19 Vaccine Trials

Government Plans Three Large Phase 3 COVID-19 Vaccine Trials

June 15, 2020

The U.S. government is planning to launch phase 3 trials of three COVID-19 vaccine candidates, starting with Moderna’s as soon as next month, followed by AstraZeneca’s AZD1222 in August, and a Johnson & Johnson candidate in September.

John Mascola, director of the Vaccine Research Center of the National Institutes for Allergy and Infectious Diseases (NIAID), said the timelines are estimates and they depend on several factors, including FDA approval to proceed.

Moderna released details last week of a planned phase 3 trial of its COVID-19 vaccine candidate in collaboration with NIAID. The Massachusetts-based drugmaker said it has finalized the protocol for the trial based on FDA feedback and expects to begin dosing next month. The trial of mRNA-1273 is expected to enroll 30,000 participants in the U.S.

Moderna has also completed enrollment of the first cohort of healthy adults ages 18 to 54 in a phase 2 study of the vaccine, as well as a cohort of adults ages 55 years and older.

AstraZeneca received a contract from HHS last month that includes funding for a phase 3 trial with 30,000 participants and a separate pediatric trial. The company declined to comment on the timing.

J&J said yesterday that it plans to begin phase 1/2a trials of its vaccine Ad26.COV2-S next month. The company also said that it is in talks with NIAID “with the objective to start phase 3 trials ahead of schedule.”

Meanwhile, NIAID Director Anthony Fauci is putting together a COVID-19 Prevention Network (CoVPN) to help speed the development of vaccines. The collaboration is based on the HIV Vaccine Trials Network (HVTN), which Fauci founded in 1998.

Larry Corey, NIAID adviser and one of the network’s leaders, said the network is looking to evaluate between five and seven vaccines. The effort will involve the HVTN, the Fred Hutchinson Center, the HIV Prevention Trials Network and the PTN Infectious Diseases Clinical Research Consortium at Emory University.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing